News Overview

BioCopy AG

Sina Kohlbrenner

BioCopy delivers new technologies for the development of vaccine precursors. Our core technique is the replication of DNA templates and the translation of these templates into proteins or peptides. Combined with label-free identification of biomolecule interactions our breakthrough technologies provide the possibility of high throughput screening of thousands of different targets at once.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.